Quelles complications peuvent survenir avec le lymphome intraoculaire ?
Les complications incluent la perte de vision, le glaucome et des infections secondaires.
ComplicationsPerte de visionGlaucome
#2
Le lymphome intraoculaire peut-il entraîner des métastases ?
Oui, il peut se propager à d'autres parties du corps, bien que ce soit rare.
MétastasesPropagationRare
#3
Comment le traitement peut-il causer des complications ?
Les traitements comme la chimiothérapie peuvent affaiblir le système immunitaire, augmentant le risque d'infections.
ChimiothérapieSystème immunitaireInfections
#4
Le suivi régulier peut-il prévenir les complications ?
Oui, un suivi régulier permet de détecter et de traiter rapidement les complications.
Suivi régulierPréventionComplications
#5
Quelles sont les complications à long terme possibles ?
Les complications à long terme peuvent inclure des problèmes de vision persistants et des effets secondaires des traitements.
Complications à long termeProblèmes de visionEffets secondaires
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque du lymphome intraoculaire ?
Les principaux facteurs incluent l'immunodépression, l'âge avancé et certaines infections.
Facteurs de risqueImmunodépressionInfections
#2
Les antécédents familiaux augmentent-ils le risque ?
Oui, des antécédents familiaux de lymphome peuvent augmenter le risque de développer la maladie.
Antécédents familiauxRisqueLymphome
#3
Les personnes immunodéprimées sont-elles plus à risque ?
Oui, les personnes immunodéprimées, comme celles atteintes du VIH, ont un risque accru.
ImmunodépressionVIHRisque accru
#4
Certaines infections virales sont-elles des facteurs de risque ?
Oui, des infections comme le virus Epstein-Barr sont associées à un risque accru de lymphome.
Infections viralesVirus Epstein-BarrRisque accru
#5
L'exposition à des produits chimiques augmente-t-elle le risque ?
Certaines études suggèrent que l'exposition à des produits chimiques peut augmenter le risque de lymphome.
Produits chimiquesExpositionRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lymphome intraoculaire : Questions médicales les plus fréquentes",
"headline": "Lymphome intraoculaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lymphome intraoculaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-30",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lymphome intraoculaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Lymphomes",
"url": "https://questionsmedicales.fr/mesh/D008223",
"about": {
"@type": "MedicalCondition",
"name": "Lymphomes",
"code": {
"@type": "MedicalCode",
"code": "D008223",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.683.515.761"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Lymphome intraoculaire",
"alternateName": "Intraocular Lymphoma",
"code": {
"@type": "MedicalCode",
"code": "D064090",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Gezhi Xu",
"url": "https://questionsmedicales.fr/author/Gezhi%20Xu",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; NHC Key Laboratory of Myopia (Fudan University); Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China."
}
},
{
"@type": "Person",
"name": "Satoru Kase",
"url": "https://questionsmedicales.fr/author/Satoru%20Kase",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan."
}
},
{
"@type": "Person",
"name": "Daiju Iwata",
"url": "https://questionsmedicales.fr/author/Daiju%20Iwata",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan."
}
},
{
"@type": "Person",
"name": "Kayo Suzuki",
"url": "https://questionsmedicales.fr/author/Kayo%20Suzuki",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan."
}
},
{
"@type": "Person",
"name": "Kenichi Namba",
"url": "https://questionsmedicales.fr/author/Kenichi%20Namba",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "No Association of Multiple Sclerosis with",
"datePublished": "2023-07-09",
"url": "https://questionsmedicales.fr/article/37511014",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241411254"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ocrelizumab for multiple sclerosis.",
"datePublished": "2022-05-18",
"url": "https://questionsmedicales.fr/article/35583174",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD013247.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Alemtuzumab for multiple sclerosis.",
"datePublished": "2023-06-05",
"url": "https://questionsmedicales.fr/article/37272540",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD011203.pub3"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Multiple sclerosis treatments].",
"datePublished": "2023-03-23",
"url": "https://questionsmedicales.fr/article/37037639",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.soin.2023.02.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Concurrent diagnoses of Tuberous sclerosis and multiple sclerosis.",
"datePublished": "2023-02-18",
"url": "https://questionsmedicales.fr/article/36863086",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.msard.2023.104586"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Syndromes immunoprolifératifs",
"item": "https://questionsmedicales.fr/mesh/D007160"
},
{
"@type": "ListItem",
"position": 4,
"name": "Syndromes lymphoprolifératifs",
"item": "https://questionsmedicales.fr/mesh/D008232"
},
{
"@type": "ListItem",
"position": 5,
"name": "Lymphomes",
"item": "https://questionsmedicales.fr/mesh/D008223"
},
{
"@type": "ListItem",
"position": 6,
"name": "Lymphome intraoculaire",
"item": "https://questionsmedicales.fr/mesh/D064090"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lymphome intraoculaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lymphome intraoculaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lymphome intraoculaire",
"description": "Comment diagnostique-t-on un lymphome intraoculaire ?\nQuels tests sont utilisés pour confirmer le lymphome intraoculaire ?\nQuels signes cliniques indiquent un lymphome intraoculaire ?\nLe lymphome intraoculaire peut-il être confondu avec d'autres maladies ?\nQuel rôle joue la biopsie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D064090?mesh_terms=Multiple+Sclerosis#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lymphome intraoculaire",
"description": "Quels sont les symptômes courants du lymphome intraoculaire ?\nLe lymphome intraoculaire cause-t-il des changements de vision ?\nPeut-on avoir des symptômes sans douleur ?\nLes symptômes peuvent-ils varier d'un patient à l'autre ?\nY a-t-il des symptômes systémiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D064090?mesh_terms=Multiple+Sclerosis#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lymphome intraoculaire",
"description": "Peut-on prévenir le lymphome intraoculaire ?\nQuels facteurs de risque sont associés au lymphome intraoculaire ?\nLes infections peuvent-elles être évitées pour réduire le risque ?\nLe dépistage précoce aide-t-il à la prévention ?\nY a-t-il des recommandations pour les personnes à risque ?",
"url": "https://questionsmedicales.fr/mesh/D064090?mesh_terms=Multiple+Sclerosis#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lymphome intraoculaire",
"description": "Quels traitements sont disponibles pour le lymphome intraoculaire ?\nLa chimiothérapie est-elle efficace pour ce type de lymphome ?\nLa radiothérapie est-elle utilisée dans le traitement ?\nQuand la chirurgie est-elle nécessaire ?\nY a-t-il des traitements expérimentaux disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D064090?mesh_terms=Multiple+Sclerosis#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lymphome intraoculaire",
"description": "Quelles complications peuvent survenir avec le lymphome intraoculaire ?\nLe lymphome intraoculaire peut-il entraîner des métastases ?\nComment le traitement peut-il causer des complications ?\nLe suivi régulier peut-il prévenir les complications ?\nQuelles sont les complications à long terme possibles ?",
"url": "https://questionsmedicales.fr/mesh/D064090?mesh_terms=Multiple+Sclerosis#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lymphome intraoculaire",
"description": "Quels sont les principaux facteurs de risque du lymphome intraoculaire ?\nLes antécédents familiaux augmentent-ils le risque ?\nLes personnes immunodéprimées sont-elles plus à risque ?\nCertaines infections virales sont-elles des facteurs de risque ?\nL'exposition à des produits chimiques augmente-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D064090?mesh_terms=Multiple+Sclerosis#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un lymphome intraoculaire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par examen ophtalmologique, imageries et biopsies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer le lymphome intraoculaire ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'échographie, l'IRM et l'analyse du liquide vitré."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un lymphome intraoculaire ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme la vision floue, des douleurs oculaires et des lésions rétiniennes peuvent indiquer la maladie."
}
},
{
"@type": "Question",
"name": "Le lymphome intraoculaire peut-il être confondu avec d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être confondu avec des infections ou d'autres tumeurs oculaires."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet d'analyser les cellules et de confirmer la présence de lymphome."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants du lymphome intraoculaire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent vision floue, douleur, rougeur et décoloration de l'œil."
}
},
{
"@type": "Question",
"name": "Le lymphome intraoculaire cause-t-il des changements de vision ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut entraîner des changements de vision, y compris des taches ou des ombres."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans douleur ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent avoir des symptômes sans douleur oculaire significative."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils varier d'un patient à l'autre ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'étendue et de la localisation du lymphome."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes systémiques associés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes systémiques comme la fièvre et la perte de poids peuvent également survenir."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le lymphome intraoculaire ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés au lymphome intraoculaire ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'immunodépression, certaines infections virales et l'âge avancé."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles être évitées pour réduire le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les infections virales comme le VIH peut réduire le risque de lymphome."
}
},
{
"@type": "Question",
"name": "Le dépistage précoce aide-t-il à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dépistage précoce peut aider à identifier les problèmes oculaires avant qu'ils ne deviennent graves."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les personnes à risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes à risque devraient consulter régulièrement un ophtalmologiste pour un suivi."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour le lymphome intraoculaire ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, la radiothérapie et parfois la chirurgie."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace pour ce type de lymphome ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la chimiothérapie est souvent efficace, surtout pour les lymphomes non hodgkiniens."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée dans le traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée pour cibler les cellules cancéreuses dans l'œil."
}
},
{
"@type": "Question",
"name": "Quand la chirurgie est-elle nécessaire ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est envisagée si le lymphome provoque des complications ou ne répond pas aux autres traitements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements expérimentaux comme les thérapies ciblées sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le lymphome intraoculaire ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la perte de vision, le glaucome et des infections secondaires."
}
},
{
"@type": "Question",
"name": "Le lymphome intraoculaire peut-il entraîner des métastases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut se propager à d'autres parties du corps, bien que ce soit rare."
}
},
{
"@type": "Question",
"name": "Comment le traitement peut-il causer des complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements comme la chimiothérapie peuvent affaiblir le système immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Le suivi régulier peut-il prévenir les complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de détecter et de traiter rapidement les complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications à long terme possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications à long terme peuvent inclure des problèmes de vision persistants et des effets secondaires des traitements."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du lymphome intraoculaire ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent l'immunodépression, l'âge avancé et certaines infections."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux augmentent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de lymphome peuvent augmenter le risque de développer la maladie."
}
},
{
"@type": "Question",
"name": "Les personnes immunodéprimées sont-elles plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées, comme celles atteintes du VIH, ont un risque accru."
}
},
{
"@type": "Question",
"name": "Certaines infections virales sont-elles des facteurs de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections comme le virus Epstein-Barr sont associées à un risque accru de lymphome."
}
},
{
"@type": "Question",
"name": "L'exposition à des produits chimiques augmente-t-elle le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que l'exposition à des produits chimiques peut augmenter le risque de lymphome."
}
}
]
}
]
}
Department of Ophthalmology, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; NHC Key Laboratory of Myopia (Fudan University); Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China.
Department of Ophthalmology, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; NHC Key Laboratory of Myopia (Fudan University); Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China.
Department of Ophthalmology, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; NHC Key Laboratory of Myopia (Fudan University); Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China.
Department of Ophthalmology, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; NHC Key Laboratory of Myopia (Fudan University); Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China.
Department of Ophthalmology, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; NHC Key Laboratory of Myopia (Fudan University); Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China.
Department of Ophthalmology, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; NHC Key Laboratory of Myopia (Fudan University); Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China.
Department of Ophthalmology, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University Eye and ENT Hospital, Fudan University, Shanghai, China; NHC Key Laboratory of Myopia (Fudan University); Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China. Electronic address: qngchang@aliyun.com.
Department of Ophthalmology and Visual Science, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Multiple Sclerosis (MS) is a common immune-mediated disorder of the central nervous system that affects young adults and is characterized by demyelination and neurodegeneration. Recent studies have as...
Ocrelizumab is a humanised anti-CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in ad...
To assess the benefits, harms, and tolerability of ocrelizumab in people with RRMS and PPMS....
We searched MEDLINE, Embase, CENTRAL, and two trials registers on 8 October 2021. We screened reference lists, contacted experts, and contacted the main authors of studies....
All randomised controlled trials (RCTs) involving adults diagnosed with RRMS or PPMS according to the McDonald criteria, comparing ocrelizumab alone or associated with other medications, at the approv...
We used standard methodological procedures expected by Cochrane....
Four RCTs met our selection criteria. The overall population included 2551 participants; 1370 treated with ocrelizumab 600 mg and 1181 controls. Among the controls, 298 participants received placebo a...
For people with RRMS, ocrelizumab probably results in a large reduction in relapse rate and little to no difference in adverse events when compared with interferon beta-1a at 96 weeks (moderate-certai...
Multiple sclerosis (MS) is an autoimmune, T-cell-dependent, inflammatory, demyelinating disease of the central nervous system, with an unpredictable course. Current MS therapies focus on treating and ...
To evaluate the benefits and harms of alemtuzumab alone or associated with other treatments in people with any form of MS....
We used standard, extensive Cochrane search methods. The latest search date was 21 June 2022....
We included randomized controlled trials (RCTs) in adults with any subtype of MS comparing alemtuzumab alone or associated with other medications versus placebo; another active drug; or alemtuzumab in...
We used standard Cochrane methods. Our co-primary outcomes were 1. relapse-free survival, 2. sustained disease progression, and 3. number of participants experiencing at least one adverse event. Our s...
We included three RCTs (1713 participants) comparing intravenous alemtuzumab versus subcutaneous interferon beta-1a for relapsing-remitting MS. Participants were treatment-naive (two studies) or had e...
Compared with interferon beta-1a, alemtuzumab may improve relapse-free survival and sustained disease progression-free survival, and make little to no difference on the proportion of participants with...
The last thirty years have led to the introduction of treatments that reduce the frequency of relapses and slow the progression of multiple sclerosis. They must be prescribed early, chosen according t...
Tuberous sclerosis (TS) is a monogenic disorder which causes disabling neurological symptoms. Similarly, multiple sclerosis (MS) may result in disability, but in contrast, is diagnosed without genetic...
The objective of this study was to develop evidence-based recommendations on pregnancy management for persons with multiple sclerosis (MS)....
MS typically affects young women in their childbearing years. Increasing evidence is available to inform questions raised by MS patients and health professionals about pregnancy issues....
The French Group for Recommendations in Multiple Sclerosis (France4MS) reviewed PubMed and university databases (January 1975 through June 2021). The RAND/UCLA appropriateness method was developed to ...
A strong agreement was reached for all 104 proposed recommendations. They cover diverse topics, such as pregnancy planning, follow-up during pregnancy and postpartum, delivery routes, locoregional ana...
The 2022 recommendations of the French MS society should be helpful to harmonise counselling and treatment practice for pregnancy in persons with MS, allowing for better and individualised choices....
The factor that is most relevant and strongly associated with the clinical course of multiple sclerosis is chronological age. Very young patients exclusively have relapsing remitting disease, whereas ...
Changes in the immune system associated with ageing are known as immunosenescence. This is characterised by a decline in immune response, chronic inflammation and an increased risk of autoimmune disea...
Multiple sclerosis is a chronic inflammatory disease of the central nervous system, caused by an autoimmune reaction. Treatment options have largely increased over the years. In this article, we prese...
The current diagnostic criteria for pediatric onset multiple sclerosis (POMS) are summarized, as well as the evidence for performance of the most recent iteration of McDonald criteria in the pediatric...